Wednesday, 21 Nov 2018

Unknown content type

What is the Future of MTX for Psoriatic Arthritis?

Like most rheumatologists, I retain a deep and abiding love for methotrexate. And with each passing decade since the drug’s ‘re-discovery’ by rheumatology, evidence for a positive trade-off between its benefits and harms has continued to accrue, ensuring its role as the centrepiece of our treatment strategies for rheumatoid arthritis, even as an avalanche of biologics and targeted synthetic DMARDs has swept over us.

Autoimmunity in the Setting of Primary Immunodeficiency

There are many avenues for interdisciplinary collaboration within rheumatology, as our specialty encompasses every organ system and diseases with protean manifestations. The intersection of rheumatology and immunology is well known and has become increasingly important, given the association of autoimmune conditions with many of the primary immunodeficiency syndromes.

ACR 2018 Podcast - Day 2B

Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTEN HERE

ACR 2018 - Day 2 Report

Monday was a packed day of sessions and studies. Here are our just a few of our highlights.

ACR 2018 Podcast - Day 1B

Audio Highlights and Interviews from Day 1 at the ACR 2018 meeting - LISTEN HERE

ACR 2018 Podcast - Day 2A

Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTEN HERE

Technology Tools for the Rheumatologist

Four years ago, the genesis of this session (technology tools for rheumatologists) was from the frustration of the archaic technologies we have been using in our medical practices (including user hostile EHRs), compared to the rapid advancing pace of the consumer technologies we use at home. So came the struggle to adapt affordable and usable consumer technology products in the office that would save time (or at least be time neutral) and impact patient management.

Is DAS28 and HAQ-DI Headed for the Graveyard?

Dr. Joseph Smolen delivered one of the most elegant and informative talk on rheumatoid arthritis at this ACR’s meeting as a tribute to Dr. Paul Klemperer. Dr. Smolen led us on a journey, and had us feeling content with what we are doing in practice as we walked with him from historical discoveries of RA through new drug development. Then Dr. Smolen did the unthinkable: he made us crash!

ACR 2018 Podcast - Day 1A

Check out the first part of our Day 1 Podcast from ACR 2018 - LISTEN HERE

Several Studies Addressed Treatment of Axial Spondylitis

Monday afternoon's session on the treatment of Axial Spondyloarthritis presented us with a great selection of studies addressing important issues in modern treatment paradigm of AxSpA. Clinical and functional improvement with IL17 inhibitors in TNF naïve patients, incidence of IBD with IL17i, TNFi retention over time were amongst topics discussed.

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.

Emerging Trends in the Treatment of Rheumatoid Arthritis

While I’m only 7 years into a (hopefully) long career in the field of rheumatology, the pace at which we are seeing advances in new medications and earlier detection of rheumatoid arthritis requires you to continually refresh your approach to the disease. 
 
We still haven’t displaced methotrexate and other conventional DMARDs, followed by TNF inhibitors for initial disease management.